Last reviewed · How we verify
PENNEL
Pennel, marketed by PharmaKing, is a therapeutic agent with a well-established presence in its indicated market. A key strength of Pennel is its patent protection, which is secured until 2028, providing a significant barrier to generic competition. The primary risk to Pennel's market position is the lack of disclosed primary indication and revenue data, which may limit strategic planning and investor confidence.
At a glance
| Generic name | PENNEL |
|---|---|
| Also known as | DDB/Garlic oil |
| Sponsor | PharmaKing |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Efficacy of DDB/Garlic Oil in Patients With Elevated Transaminase Chronic Liver Disease (PHASE4)
- Study to Evaluate Efficacy and Safety of PENNEL Capsule in the Patients With Chronic Liver Disease (PHASE3)
- Study to Evaluate Efficacy, Safety and Tolerability of PENNEL Capsule in the Patients With Chronic Liver Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PENNEL CI brief — competitive landscape report
- PENNEL updates RSS · CI watch RSS
- PharmaKing portfolio CI